The rising geriatric population and increasing health expenditure have accelerated the need for cancer spit test devices in healthcare facilities. The surging volume of cancer patients and the rising prevalence of chronic diseases are also propelling the market's growth. The global cancer spit test devices market is growing in the forecast year due to the rising players in the market and the availability of advanced products. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-cancer-spit-test-device-market
Global Cancer Spit Test Devices Market is expected to reach USD 1,019.38 million by 2028 from USD 506.76 million in 2020, growing at a substantial CAGR of 9.7% in the forecast period of 2021 to 2028. The rising geriatric population and increasing health expenditure have accelerated the need for cancer spit test devices in healthcare facilities. The surging volume of cancer patients along with the rising prevalence of chronic diseases is also propelling the growth of the market. The global cancer spit test devices market is growing in the forecast year due to the rising players in the market and the availability of advanced products. Along with this, manufacturers are engaged in R&D activity for launching novel products in the market.
High prevalence and disease burden of cancer across the world will drive the market's growth rate
Cancer is the rampant progress of aberrant cells anywhere in the body. These aberrant cells are known as tumor cells, malignant cells, or cancer cells. Liver, stomach, colorectal, prostate, and lung cancer are some of the most general cancers in men, whereas thyroid, cervical, lungs, colorectal, and breast cancers are the most general cancers among females. Furthermore, cancer is the second leading reason of death across the globe. Hence, the growing prevalence of cancer disease demands advanced cancer treatment, whereas cancer treatment such as chemotherapy induces severe risk factors and adverse effects on the patient. Adverse effects include anemia, nausea, vomiting, and various infectious diseases.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Saliva Collection Kits, Fluid Specific Devices, Oral Swab, Bar-Code Labels, Saliva Cryostorage Box, and Others), Site Of Collection (Sub-Mandibular/Sub-Lingual Gland, Parotid Gland, and Minor Salivary Gland), Application (Liver-Lung Cancer, Breast Cancer, Colon And Rectal Cancer, Prostate Cancer, Pancreatic Cancer, Oral Cancer, Thyroid Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Melanoma, Non-Hodgkin Lymphoma, and Others), Age Group (Adult and Pediatric), Method Of Collection (Passive Drool, Oral Swab, and Others), End User (Hospitals, Diagnostic Laboratories, Oncology Speciality Clinics, Cancer Research Institutes, and Others), Distribution Channel (Direct Tenders, Retail Sales, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
|
Market Players Covered
|
DNA Genotek (Canada), Salimetrics, LLC (U.S.), PeriRx (U.S.), Color Health, Inc. (U.S.), SARSTEDT AG. Co. KG (Germany), Miraclean Technology Co.,Ltd. (China), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN, Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), BD (U.S.), Biocartis (Belgium), bioMérieux SA (France), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Oasis Diagnostics Corporation (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework
|
Segment Analysis:
Global cancer spit test devices market is categorized into seven notable segments which are based on product type, site of collection, application, age group, method of collection end-user, and distribution channel.
- On the basis of product type, the global cancer spit test devices market is segmented into saliva collection kits, fluid specific devices oral swab, bar-code labels, saliva cryostorage box, and others. In 2021, saliva collection kits segment is expected to dominate the Global cancer spit test devices market with 39.9% market share due to increasing demand for POCT devices and the rising prevalence of cancer patients.
- On the basis of site of collection, the global cancer spit test devices market is segmented into sub-mandibular/sub-lingual gland, parotid gland and minor salivary gland. In 2021, sub-mandibular/sub-lingual gland segment is expected to dominate the global cancer spit test devices market with 63.9% market share because of better patient compliance and increasing healthcare expenditure.
- On the basis of application, the global cancer spit test devices market is segmented into liver-lung cancer, breast cancer, colon and rectal cancer, prostate cancer, pancreatic cancer, oral cancer, thyroid cancer, endometrial cancer, kidney cancer, leukemia, melanoma, non-hodgkin lymphoma In 2021, liver-lung segment is expected to dominate the Global cancer spit test devices market with 26.2% market share because of the rising incidence of liver cirrhosis and chronic diseases.
- On the basis of age group, the global cancer spit test devices market is segmented into adult and pediatrics. In 2021, adult segment is expected to dominate the Global cancer spit test devices market with 81.1% market share because of the rising geriatric population.
- On the basis of method of collection, the global cancer spit test devices market is segmented into passive drool, oral swab and others. In 2021, passive drool segment is expected to dominate the Global cancer spit test devices market with 59.1% market share because it is easy to use and non-invasiveness method.
- On the basis of end user, the global cancer spit test devices market is segmented into hospitals, diagnostic laboratories, oncology specialty clinics, cancer research institutes. In 2021, the hospitals segment is expected to dominate the Global cancer spit test devices market with 40.7% market share because of the rising demand for cancer saliva testing devices in the healthcare sectors.
The hospitals segment will dominate the end user segment of the cancer spit test devices market
The hospitals segment will emerge as the dominating segment end user segment. This is because of the growing number of clinics in the market especially in the developing economies. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
- On the basis of distribution channel, the global cancer spit test devices market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is expected to dominate the global cancer spit test devices with 71.9% market share because of the large number of major players in the market.
The direct tender segment will dominate the distribution channel segment of the cancer spit test devices market
The direct tender segment will emerge as the dominating segment under distribution channel. This is because of the growing number of infrastructural development activities in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in market: DNA Genotek (Canada), Salimetrics, LLC (U.S.), PeriRx (U.S.), Color Health, Inc. (U.S.), SARSTEDT AG. Co. KG (Germany), Miraclean Technology Co.,Ltd. (China), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN, Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), BD (U.S.), Biocartis (Belgium), bioMérieux SA (France), Siemens Healthcare GmbH (Germany), F. Hoffmann-La Roche Ltd (Switzerland), and Oasis Diagnostics Corporation (U.S.).
Market Development
- In January 2021, DNA Genotek announced today that the U.S. Food and Drug Administration (FDA) has granted a general use 510(k) clearance for its OrageneDx family of products. This FDA approval has increased the credibility of the company in the market and increased the sales and demand of this product.
- In February 2021, Thermo Fisher Scientific was recognized with Six CMO Leadership Awards. It won across all six categories, including capabilities, compatibility, expertise, quality, reliability and service. This is the second consecutive year Thermo Fisher has received this recognition across all six categories and the eighth time overall that the company has been honored by the CMO Leadership Awards. This has increased the credibility of the company and aids in revenue generation.
Regional Analysis
Geographically, the countries covered in the market report are U.S., Canada, Mexico in North America, Germany, Sweden, Poland, Denmark, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe in Europe, Japan, China, India, South Korea, New Zealand, Vietnam, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), Brazil, Argentina, Rest of South America as a part of South America, UAE, Saudi Arabia, Oman, Qatar, Kuwait, South Africa, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
As per Data Bridge Market Research analysis:
North America is the dominant region in cancer spit test devices market during the forecast period 2021 to 2028
The majority of the market was in North America. This is due to the increasing prevalence of chronic diseases in the region. One of the main potential growth elements thought to be responsible for the prevalence of advanced healthcare infrastructure.
Asia-Pacific is estimated to be the fastest growing region in cancer spit test devices market the forecast period 2021 to 2028
Over the forecast period, Asia-Pacific is anticipated to grow at a profitable pace. The significant growth is linked to rising healthcare costs. The regional market is growing because of increasing number of cancer cases in the region.
COVID-19 Impact
As a result of rising rates of infectious diseases among people, new product introductions, and a rising desire for self-saliva-based and non-invasive testing, the COVID-19 epidemic has had a favorable effect on the industry. A viable alternative biological sample for the diagnosis of COVID-19 is saliva. Patients generally accept saliva collection since it may be done without personal protective equipment (PPE) or the assistance of medical professionals and can be done by the patients themselves. The expanding industry has several lucrative potential because of the growing requirement to diagnose COVID-19-infected patients.
For more detailed information about the cancer spit test devices market, visit: https://www.databridgemarketresearch.com/jp/reports/global-cancer-spit-test-device-market
